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Abstract
Insulin-like growth factors (IGF) have mitogenic and
antiapoptotic functions, and may be involved in tumor
growth. The purpose of the study was to investigate the
role of IGF components in seminoma compared to
normal testis. Normal testicular tissues from autopsy
cases and seminoma from surgery caseswere obtained
for microarray and real-time reverse transcription
polymerase chain reaction (RT-PCR) analysis of IGF-1,
IGF-2, IGF receptor type 1 (IGF-R1), IGF-R2, insulin
receptor isoforms A (IR-A) and B (IR-B), and IGF-
binding proteins (IGFBP) 1–6. IGF-2 was localized by
immunohistochemistry. IGFBP-5 protein expression
was evaluated by Western blot analysis. mRNA ex-
pression in microarray and real-time RT-PCR showed
similar tendencies: IGF-1, IGF-R1, IGF-R2, IR-A, and
IGFBP-2 were not different in both groups. IGF-2, IR-B,
IGFBP-1, IGFBP-4, and IGFBP-6 mRNA were down-
regulated in seminoma. IGFBP-3 tended to be upregu-
lated in pT1 seminoma, but downregulated in pT2
stages. IGFBP-5 and IGF-2 protein expression corre-
lated with mRNA expression. In conclusion, down-
regulation of mainly inhibiting IGFBPs may allow a
stimulated tumor growth. The downregulated IGF-2
does not seem to be involved in the growth regula-
tion of seminoma. Constantly expressed genes (e.g.,
IGF-1, IGF-R1, IR-A, and IGFBP-2) may reflect an in-
volvement in spermatogenesis, but may also play a
major role in tumor growth as their expression is not
downregulated despite the lack of spermatogenesis in
tumor tissue.
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Introduction
Insulin-like growth factors (IGF) exhibit strong mitogenic
and antiapoptotic effects and therefore have an important
impact on tumor growth. They do not only influence tumor
growth, but also migration and adhesion of tumor cells.
Many tumors are associated with elevated IGF plasma
levels and exhibit an increased local expression of IGF or
IGF receptor type 1 (IGF-R1) [1]. IGF-R1 is a tyrosine kinase
receptor, which mediates growth-stimulating effects of IGF-1
and IGF-2, such as mitogenesis, cell transformation, cell differ-
entiation, and antiapoptosis [2]. Contrary to IGF-R1, the type 2
receptor, IGF-R2, exclusively binds IGF-2 and serves for the
internalization and degradation of IGF-2 [3]. Especially locally
produced IGF-2 seems to have important proliferating effects
on several cancer entities, such as ovarian, mammary, pros-
tate, and thyroid cancers [4–8]. The mitogenic effects of IGF-2
do not only seem to be transmitted by IGF-R1, but also in an
important degree by the isoform A of the insulin receptor (IR-A)
[5,8]. This autocrine loop may be an additional stimulator for
tumor growth.
IGF-binding proteins (IGFBP) can have both inhibiting and
stimulating properties on IGF function. Different phosphoryla-
tion stages of the IGFBP influence their affinity for binding IGF,
so that the IGF function may be raised or inhibited. The activity
and availability of IGFBP may further be affected by different
partly specific proteases. Some of the IGFBP have their own
receptors (e.g., IGFBP-3 and IGFBP-5) that allow them to bind
and directly affect the cell. The intrinsic action of IGFBP-1 may
be mediated by a5 b1 integrin [9]. IGFBP-3 is the main intra-
vascular carrier and storage for IGF-1. Receptor binding of IGF
is anticipated by forming complexes with acid labile subunit
(ALS). IGFBP-4 is a soluble extracellular binding protein that
inhibits the IGF/IGF binding site interaction by sequestering
IGF. IGFBP-6 differs from the other binding proteins insofar as
it is binding IGF-2 with 100-fold higher affinity than IGF-1 [10].
Zhou and Bondy [11] localized the mRNA of the IGF system
in normal testicular tissue. IGF-R1 and IGF-R2 mRNA were
most abundant in the germinal epithelium, whereas IGF-1 and
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IGFBP-1 mRNA could not be detected with the applied in situ
hybridization. In contrast, immunohistochemistry showed
IGF-1 staining in Sertoli cells, primary spermatocytes, and
some Leydig cells [12]. The authors also demonstrated
positivity for IGF-R1 in secondary spermatocytes, early sper-
matids, Sertoli cells, and some Leydig cells. In germ cell
tumors, IGF-2 mRNA could be found in two of three semi-
noma [13]. The strongest IGF-2 expression in this study was
seen in one embryonal carcinoma. Drescher et al. [14]
investigated the distribution of the IGF system in carcinoma
in situ (CIS) of the testis using immunohistochemistry. They
found the strongest staining for IGFBP-5 compared to the
other IGFBP, and therefore postulated an important role
for IGFBP-5 by assuming an proliferative advantage for
the CIS cells.
Systematic studies on the IGF system in normal testicular
tissue and seminoma have not been performed until now. To
address this issue, the goal of this study was to quantita-
tively compare the expression of the IGF system in normal
testicular tissues and seminoma with emphasis on the
autocrine growth promoter, IGF-2, and the possibly stimu-
lating IGFBP-5, and to derive their meaning for the tumor
growth of seminoma.
Materials and Methods
Tissue Collection
Normal testicular tissue (n = 9) was collected from au-
topsy cases (age: 34–75 years). The selected patients died
of myocardial infarction, heart failure, stroke, or ileus. Intact
spermatogenesis was verified in histologic examination.
Bodies were cooled at 4jC within 2 hours after death, and
tissue samples were snap-frozen in liquid nitrogen with the
beginning of autopsy. Seminoma tissue (n = 22) was col-
lected from operation specimens of patients with pure classic
seminoma (age: 21–62 years). All patients underwent sur-
gery between 1998 and 2002 at the Department of Urology,
University Hospital Mannheim (Mannheim, Germany). Pa-
tients’ informed consent was taken prior to all investigations.
Histologic diagnosis and evaluation of the tumor stage were
performed by conventional light microscopy. Eight pT1 and
14 pT2 stages were identified. Whereas pT1 stages of
seminoma are limited to the testis and epididymal tissues,
pT2 stages are characterized by hemangioinvasion or lym-
phangioinvasion, or by infiltration of the tunica vaginalis.
Tissue samples were taken after surgical removal, snap-
frozen in liquid nitrogen within 30 minutes, and stored at
80jC until RNA extraction. Histologic characterization and
purity of all samples were verified by frozen sections before
RNA extraction.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA from 30 mg of normal testicular tissue (n = 9)
and seminoma (n = 22) was extracted using the RNeasy Mini
Kit (Qiagen GmbH, Hilden, Germany) following the animal
tissue protocol of the manufacturer’s instructions. Tissue
lysates were homogenized with the QIAshredder (Qiagen).
RNA was dissolved in water and spectroscopically quantified
at 260 nm with the Ultrospec 3100 Pro (Biochrom Ltd.,
Cambridge, UK). The purity of RNA was verified by optical
density (OD) absorption ratio OD260 nm/OD280 nm between
1.80 and 2.06 (mean = 2.0). RNA quality was analyzed using
the RNA 6000 Nano LabChip Kit (Agilent Technologies
GmbH, Bo¨blingen, Germany) and the Agilent 2100 bioana-
lyser (Agilent Technologies GmbH) for electrophoretic sep-
aration. The 28S/18S rRNA ratio of all samples was between
1.7 and 2.0 (mean = 1.84). RNA quality of samples gained
by autopsy and surgery, respectively, did not differ, and only
samples with good quality RNA were used for the following
reverse transcription reaction.
Constant amounts of 1 mg of total RNA were reverse-
transcribed with 200 U of M-MLV Reverse Transcriptase
(Promega Corp., Madison, WI) and Random Primers (Pro-
mega Corp.) according to the manufacturer’s instructions. All
investigated samples were transcribed in the same reverse
transcription reaction.
The specific primers for quantitative real-time PCR were
designed using publicly available sequences from the Nu-
cleotide Sequence Database, NCBI [insulin receptor (IR):
accession no. AH002851; IGFBP-1: accession no. M74587;
IGFBP-3: accession no. NM_000598; IGFBP-5: accession
no. NM_000599; and IGFBP-6: accession no. NM_002178]
or used according to literature [15] (Table 1). A master mix
was prepared as follows: 6.4 mL of water, 1.2 mL of MgCl2
(25 mM), 0.2 mL of forward primer (20 mM), 0.2 mL of reverse
primer (20 mM), and 1.0 mL of LightCycler Fast Start DNA
Master SYBR Green I (Roche Diagnostics, Mannheim,
Germany). Nine microliters of the master mix was filled in
glass capillaries and 1 mL of PCR template containing 25 ng
of reverse-transcribed total RNA was added. To ensure
an accurate quantification of the desired product, a high-
temperature fluorescence measurement in a fourth seg-
ment of the PCR run was performed [16]. The following
general real-time PCR protocol was employed: denaturation
for 10 minutes at 95jC; 40 (IGF-2, IGFBP-2, IGFBP-3, and
IGFBP-5), 45 (IGF-1, IGF-R1, IR, IR-A, IR-B, IGFBP-1,
IGFBP-4, and IGFBP-6), or 80 (IGF-R2) cycles of a four-
segment amplification and quantification program; a melting
step by slow heating from 60jC to 99jCwith a rate of 0.1jC/s
and continuous fluorescence measurement; and a final
cooling down to 40jC. The four-segment amplification and
quantification program was carried out as follows: 15 sec-
onds of denaturation at 95jC; 10 seconds of annealing at
58jC (IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-5, and IGFBP-6),
60jC (IGF-R2, IR-A, and IR-B), 62jC (IGF-1, IGF-2, and IR),
63jC (IGF-R1), and 66jC (IGFBP-4), respectively; 15 sec-
onds of elongation at 72jC; and 5 seconds of fluores-
cence acquisition at 80jC (IGFBP-1), 81jC (IGFBP-3),
84jC (IGF-R1), 85jC (IR, IR-A, IR-B, and IGFBP-5), 86jC
(IGFBP-6), 87jC (IGF-R2), 88jC (IGF-1 and IGFBP-2), and
89jC (IGF-2 and IGFBP-4), respectively. Crossing point (CP)
values were acquired by using the second derivative maxi-
mum method of the LightCycler Software 3.5 (Roche Diag-
nostics). CP is the number of PCR cycles when maximal
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acceleration of the fluorescence increase is reached. The
earlier the fluorescence increases, the higher is the concen-
tration of the measured mRNA. All CP of the 31 samples per
investigated factor were detected in one run to eliminate
interassay variance. Real-time PCR efficiencies were ac-
quired by amplification of a standardized dilution series of
the template cDNA and the given slopes in the LightCycler
Software 3.5 (Roche Diagnostics). The corresponding effi-
ciencies (E ) were then calculated according to the equation:
E = 10[1/slope] [17]. The specificity of the products was
documented with a high-resolution gel electrophoresis and
analysis of the melting temperature, which is product-specific
[15] (for specific melting temperatures, see Table 1). PCR
products were purified with the Nucleo Spin Extraction Kit
(Macherey-Nagel, Du¨ren, Germany) and sent for commer-
cial sequencing (GENterprise GmbH, Mainz, Germany). The
results were compared to the known sequences in the
NCBI database.
Microarray
The gene expression profiles of 40 seminoma of different
stages [pT1 (n = 22), pT2 (n = 14), and pT3 (n = 4)] were
compared with normal testicular tissue (n = 3) using tissue
homogenates and cDNA microarrays focusing on the ex-
pression of the IGF-associated genes. One of these normal
testicular tissues and 17 of the seminoma specimens were
part of the sample collective in Mannheim taken for real-time
RT-PCR investigations. Tissue samples were taken from
patients aged 25 to 58 years. All patients underwent surgery
between 1995 and 2002 at the Department of Urology in
Mannheim, Essen, or Mu¨nster. Patients’ informed consent
was taken prior to all investigations.
Testicular tissues used for microarray analyses were
lysed in TRIzol (Life Technologies, Karlsruhe, Germany)
and total cellular RNA was prepared using the RNeasy Mini
Kit (Qiagen), according to the manufacturer’s protocol. RNA
quality was controlled spectrophotometrically and by gel
electrophoresis. Preparation of cDNA targets starting from
5 to 10 mg of total RNA, fragmentation, hybridization to HG-
U95Av2 arrays, washing, staining, and scanning were per-
formed following the manufacturer’s protocols. Expression
values (signal and detection calls: A—absent; P—present;
and M—marginal) were obtained by performing the absolute
analysis using Affymetrix microarray Suite Version 5.0. This
includes the background correction of the average of the
lowest two percentiles of intensities on a four-by-four grid on
the chip, the introduction of an ‘‘ideal mismatch’’ forced to be
lower than the corresponding perfect match, and the usage
of Tukey’s biweight to elicit an expression value out of single
probe intensity pairs. Global scaling was applied to allow
comparison of gene signals across multiple microarrays.
Annotation of the probe sets was taken from the annotation
files provided on the Affymetrix homepage [18].
Immunohistochemistry
Immunohistochemistry was performed in nine normal
testicular tissues and 22 seminoma using a mouse mono-
clonal antibody to human IGF-2 (clone W3D9; Serotec Ltd.,
Oxford, UK). Cross reactivity with human IGF-1 and insulin is
< 0.01%. Tissue samples were fixed in Bouin’s solution for
24 hours at room temperature (21jC) and embedded in par-
affin wax after dehydration. Sections of 3 mm were incubated
with the IGF-2 antibody at a 1:40 dilution at 4jC overnight.
Immunoreactive sites were detected using incubation with
Table 1. Primer Sequence, Product Length, Product-Specific Melting Temperature, Real-Time PCR Efficiency, Mean (n = 31) Coefficient of Variation in % (CV%),
and Range of Crossing Points (CP) in Human Testis and Seminoma, Respectively, for the Investigated Factors.
Factor Primer Sequence Length (bp) Melting Temperature (jC) PCR Efficiency Mean CV% CP Range
IGF-1 For 5V-TCGCATCTCTTCTATCTGGCCCTGT-3V 240 90.4 1.73 6.97 28.98–33.91
Rev 5V-GCAGTACATCTCCAGCCTCCTCAGA-3V
IGF-2 For 5V-GACCGCGGCTTCTACTTCAG-3V 203 91.8 1.89 11.3 20.31–31.05
Rev 5V-AAGAACTTGCCCACGGGGTAT-3V
IGF-R1 For 5V-TTAAAATGGCCAGAACCTGAG-3V 314 87.2 2.15 1.45 31.06–34.78
Rev 5V-ATTATAACCAAGCCTCCCAC-3V
IGF-R2 For 5V-TACAACTTCCGGTGGTACACCA-3V 144 88.3 – 6.90 55.71–64.68
Rev 5V-CATGGCATACCAGTTTCCTCCA-3V
IR For 5V-GCTGAAGCTGCCCTCGAGGA-3V 290 + 254 87.6 1.88 4.58 22.23–27.53
Rev 5V-CGGCCACCGTCACATTCCCA-3V
IR-A For 5V-GCTGAAGCTGCCCTCGAGGA-3V 210 87.0 1.87 3.94 22.61–27.32
Rev 5V-CGAGATGGCCTGGGGACGAA-3V
IR-B For 5V-GCTGAAGCTGCCCTCGAGGA-3V 244 87.0 1.99 4.86 23.59–30.54
Rev 5V-AGATGGCCTAGGGTCCTCGG-3V
IGFBP-1 For 5V-TCAAAAAATGGAAGGAGCCCT-3V 127 82.3 2.12 2.22 30.18–33.78
Rev 5V-AATCCATTCTTGTTGCAGTTT-3V
IGFBP-2 For 5V-CACCGGCACATGGGCAA-3V 136 90.0 1.98 3.19 26.50–31.40
Rev 5V-GAAGGCGCATGGTGGAGAT-3V
IGFBP-3 For 5V-CTACAAAGTTGACTACGAGTC-3V 139 84.3 1.73 5.74 24.47–30.05
Rev 5V-ACTCAGCACATTGAGGAACTT-3V
IGFBP-4 For 5V-GCCCTGTGGGGTGTACAC-3V 342 92.7 1.55 7.18 31.60–36.87
Rev 5V-TGCAGCTCACTCTGGCAG-3V
IGFBP-5 For 5V-AGCAAGTCAAGATCGAGAGAGA-3V 154 88.5 1.64 5.75 23.23–30.76
Rev 5V-TTCTTTCTGCGGTCCTTCTTCA-3V
IGFBP-6 For 5V-AGAGGAGAATCCTAAGGAGAGT-3V 229 89.5 1.66 5.64 25.44–33.27
Rev 5V-ATTGGGCACGTAGAGTGTTTGA-3V
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a 1:1000 dilution of biotin SP–conjugated goat antimouse
IgG/IgM (Jackson Immuno Research, West Grove, PA) for
30 minutes at room temperature (21jC) and subsequent in-
cubation with streptavidin-conjugated alkaline phosphatase
(Jackson Immuno Research) diluted to 1:250 at room tem-
perature (21jC) for 30 minutes. Immunoreactive sites were
developed using Fuchsine substrate chromogen (Dako,
Glostrup, Denmark). Sections were counterstained with
haematoxylin andmounted in Kaiser’s glycerol gelatin (Merck,
Darmstadt, Germany). Stained slides were examined to iden-
tify the cellular localization of IGF-2 immunoreactivity.
Western Blot
Samples of frozen tumor (n = 22) and normal testicular
tissue (n = 9) were homogenized in lysis buffer (150 mM
NaCl, 105 mM ethylenediaminetetraacetate, 3% glycerol,
1 mg/ml bovine serum albumin, 1% IGEPAL CA-630; Sigma-
Aldrich Chemie, Steinheim, Germany). After determination
of the protein concentration using a Bradford assay, a
cocktail of proteinase inhibitors [1 mg/ml leupeptin (Amer-
sham Pharmacia Biotech, Freiburg, Germany), 5 mg/ml
aprotinin (Roth, Karlsruhe, Germany), 2 mg/ml pepstatin A
(Amersham Pharmacia Biotech), and 0.5 mM pefabloc
(Roche Diagnostics)] was added. From each sample, 20 mg
of total protein was separated on 18% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to PVDF membranes. The membranes were
blocked with 3% skim milk (Slimfast, Wiesbaden, Germany)
and incubated overnight at room temperature (21jC) with a
rabbit polyclonal anti–human IGFBP-5 antibody (Upstate,
Lake Placid, NY) at a dilution of 1:1000. After thorough
washing, an alkaline phosphatase-conjugated goat anti rab-
bit antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
was applied at a 1:1000 dilution for 60 minutes at room
temperature (21jC). Bands were visualized using 5-bromo-
4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/
NBT) (Roche Diagnostics) in AP buffer (100 mM Tris–HCl,
pH 8.0, 100 mM NaCl, and 50 mMMgCl2). The expression of
IGFBP-5 was densitometrically analyzed with the AIDA 1D
Software (AIDA; Raytest Isotopenmessgera¨te GmbH, Strau-
benhardt, Germany).
Statistical Analysis
Evaluation of the real-time PCR results. Data were analyzed
by the Relative Expression Software Tool (REST) for group-
wise comparison and statistical analysis of relative expres-
sion results in real-time PCR [19]. This software calculates
an expression ratio in regard to the control group (normal
testicular tissue). The expression ratio (R) is:
R ¼ EDCP target ðMean ControlMean SampleÞtarget =
E
DCP reference ðMean ControlMean SampleÞ
reference
with E = efficiency. REST also indicates coefficients of
variation (CV) in percent and standard deviations based on
the CP of the target gene. The data are shown as a maximal
cycle number of 40 minus the acquired CP ± SEM. The
higher the 40  CP values, the higher is the concentration
of the target gene. As PCR amplification is an exponen-
tial process, a difference of two CP (DCP = 2) signifies ap-
proximately a regulation by a factor of E
2
(with E = efficiency)
and is indicated in the text according to the expression
ratio calculated by REST.
Evaluation of microarray results. Exploratory data analysis,
Wilcoxon paired nonparametric tests for difference, and
the Mann-Whitney test for the nonparametric independent
two-group comparisons were performed with the program
SPSS 10 for Windows (SPSS, Inc., Chicago, IL) and Micro-
soft Excel 2000 (Microsoft Corp., Redmond, WA). Differ-
ences with P < .05 were regarded as statistically significant.
Evaluation of Western blot results. Data were tested with the
Mann-Whitney rank sum test. Differences with PV .001 were
regarded as highly significant. The data are shown as OD,
calculated as integral (Int) minus background (Bkg).
Results
Real-Time PCR
The investigated transcripts showed high real-time PCR
efficiencies, low coefficients of variation (CV%), CP ranges
from 20.31 to 36.87 and 65.87, respectively (Table 1), and a
good linearity over the range of 0.2 to 50 ng of cDNA input.
IGF-1 (Figure 1) and IGF-R1 (data not shown) mRNA
showed no significantly different expressions in normal
testis and seminoma. IGF-2 mRNA was significantly down-
regulated in seminoma by a factor of 16 (P < .001), with a
maximal downregulation in pT2 stages by a factor of 21
(P < .001) (Figure 1). IGF-R2 expressions were not signifi-
cantly different between groups and very low with CP be-
tween 55.71 and 65.68 (data not shown). Amplification with
the IR primer pair showed the two isoforms of the insulin
receptor with stronger expression of the smaller isoform,
IR-A (Figure 2). Specific amplification of the two isoforms
revealed a constant expression of IR-A in both normal
testicular tissue and seminoma, and a downregulation of
IR-B in seminoma (P < .001) with maximal downregulation
by a factor of 8 (P < .001) in pT2 stages (Figure 1).
IGFBP-1 mRNA was downregulated by a factor of 3
(P < .001), with a maximal 3.5-fold (P < .001) downregu-
lation in pT2 stages (Figure 3). There were no significant dif-
ferences in IGFBP-2 expression between groups. IGFBP-3
expression showed a slight increase in pT1 stages but a
significant downregulation by a factor of 2 (P < .05) in pT2
stages when compared to normal testis. Further, IGFBP-3
was significantly downregulated by a factor of 2.4 (P < .01) in
pT2 stages, when compared to pT1 stages. IGFBP-4 was
downregulated in seminoma by a factor of 1.8 (P < .01).
Although the downregulation of IGFBP-4 was not significant
between pT1 stages and the control group, it became
significant (P < .01) when comparing pT2 stages with the
control group (downregulation by a factor of 2.1). IGFBP-5
mRNA expression was downregulated by a factor of 3.1
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(P < .001) in seminoma with a maximal downregulation by
a factor of 4 (P < .001) in pT2 stages. IGFBP-5 mRNA was
significantly downregulated by a factor of 1.9 (P < .05) in pT2
stages compared with pT1 stages. There is a significant
downregulation by a factor of 1.7 (P < .05) for IGFBP-6
expression in seminoma, but there was no significant differ-
ence when comparing pT1 and pT2 stages separately with
normal testicular tissue.
Microarray
Microarray analysis identified regulated genes in three
normal testicular specimens and 40 seminoma of different
stages [pT1 (n = 22), pT2 (n = 14), and pT3 (n = 4)]. The
gene expression profiles of four samples of tumor stage
pT1 were compared with those of three normal testicular
tissue samples resulting in 12 single comparisons represen-
tative for the 43 samples investigated. The expression of
1490 probe sets was determined as differentially expressed
in at least 80% of the comparisons with a P value of < .001
and > .999 for 635 increased changes and 855 decreased
changes, respectively. Furthermore, we focused on the
regulation of the expression of the following IGF-related
genes: IGF-1, IGF-2, IGF-R1, IGF-R2, IGFBP-1, IGFBP-2,
IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6 (Table 2).
IGF-1 and IGF-R1 were constantly expressed in semi-
noma and normal testicular tissue. Two of three probe sets
for IGF-2 were under the threshold level of the microarray.
The third probe set covered exon 1 of four and showed a
slight increase in expression from normal testis to seminoma
(P = .066) with a significant difference between normal
testicular tissue and tumor stage pT1 (P = .046), as well as
between pT1 and pT3 (P = .009). The IGF-R2 gene was
constantly expressed in all 43 samples.
There were no significant differences in the expression
of IGFBP-1 and IGFBP-2 between the different groups.
IGFBP-2 mRNA expression correlated significantly (r =
0.64 and r = 0.564, P V .001) with IGF-R1 mRNA. The
expression of IGFBP-3 was measured on two probe sets
and showed a significant increase (P V .05) from normal
testicular tissue to seminoma tissues with tumor stage
pT1 in one probe set and decreasing tendencies during
further tumor progression. Similar tendencies were identi-
fied for the expression of IGFBP-4 with a slight increase in
pT1 stages and a decrease (P V .05) from pT1 to pT2
stages. The expression of both genes (IGFBP-3 and
IGFBP-4) correlated significantly in all 43 samples. Con-
sidering the different probe samples giving inconsistent
data (Table 2), the expression of IGFBP-5 showed a
decreasing tendency in seminoma when compared to
normal testicular tissue. The hybridization intensity in three
of five probe sets with positive IGFBP-5 was significantly
decreased in seminoma stages pT1 and pT2 when com-
pared to normal testicular tissue. IGFBP-6 was constantly
expressed in seminoma and normal testicular tissue.
DLK1 (delta Drosophila homolog-like 1 gene) and the
insulin-like hormone INSL3 are expressed by Leydig cells
[20,21], whereas follicle-stimulating hormone receptor
(FSH-R) and androgen receptor (AR) are expressed by
Sertoli cells [22,23] and therefore act as Leydig cell and
Sertoli cell markers, respectively. IGF-R1 and IGF-2 cor-
related positively with FSH-R, whereas IGFBP-3 showed
a negative correlation with FSH-R and AR (Table 3).
Figure 1. Expression data (mRNA) for IGF-1, IGF-2, IR-A, and IR-B in normal testicular tissue and pT1, pT2, and pT1 + pT2 stages of seminoma. Data are shown
as a maximal cycle number of 40 minus the acquired crossing point (40  CP) ± SEM. Significance is indicated as follows: ***P < .001.
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IGFBP-5 correlated positively with both FSH-R/AR and
DLK3/INSL3.
Table 4 summarizes the results from the microarrays in
comparison with real-time RT-PCR.
Immunohistochemistry
Normal testicular tissue showed strong cytoplasmatic
IGF-2 staining in primary and secondary spermatocytes
and rarely in some Sertoli cells in terms of paranuclear dots
(Figure 4A) accumulating in a cuneiform fashion. Spermato-
gonia and spermatids were negative. All tubules were posi-
tive with approximately 30% to 50% of the spermatocytes
per tubule expressing IGF-2. Typical staining was also seen
in tumor adjacent tissues of seminoma cases, if there was
still any intact spermatogenesis. Most of the tumor cases
showed ‘‘burned out’’ tubules with nonmaturating germ cells
or Sertoli cells only in the adjacent tumor-free tissue. In two
cases, parts of the epididymis could be assessed as well:
the rete testis and the efferent ductuli showed a strong
luminal staining of the epithelia in a vesicular manner, and
the epididymal duct showed a distinct staining of basal cells
of its epithelial cell layer.
Tumor cells in all investigated seminoma were weakly
positive with a rather diffuse cytoplasmatic staining for IGF-2
Figure 2. Specific PCR products for IR (290 + 254 bp), amplifying both insulin
receptor isoforms, IR-A (210 bp) and IR-B (244 bp). M = marker; W = water.
Notice the pronounced expression of the smaller isoform in the IR product.
Figure 3. Expression data (mRNA) for IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, and IGFBP-6 in normal testicular tissue and pT1, pT2, and pT1 + pT2
stages of seminoma. Data are shown as a maximal cycle number of 40 minus the acquired crossing point (40  CP) ± SEM. Significance is indicated as follows:
*P < .05, **P < .01, and ***P < .001.
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(Figure 4B). The staining appeared less intensive than in
normal testicular tissue. Some endothelial cells of smaller
capillaries showed a clear positive staining for IGF-2, also in
terms of a paranuclear vesicle.
Western Blot
Western blot analysis of IGFBP-5 showed a weak protein
expression in seminoma and a strong protein expression in
normal testicular tissue (P < .001). Both pT1 and pT2 stages
are significantly downregulated (both P < .001) when com-
pared separately with normal testicular tissue. IGFBP-5
protein expression in pT1 stages compared to pT2 stages
was not significantly different but showed a slight decrease
in pT2 stages (median pT1 = 0.26, median pT2 = 0.24).
Figure 5 shows a representative blot with the IGFBP-5–
specific band at 31 kDa.
Discussion
The differential expression of IGF, their binding proteins, and
receptors in normal versus seminoma tissue has been
investigated. Protein and mRNA of IGFBP-5 showed the
same expression pattern in normal testicular tissue and
seminoma. Regarding the immunohistochemical expression
profile of IGF-2, the strong IGF-2 expression in normal
testicular tissue and the lower expression in tumor tissue,
as seen in real-time PCR, seem to be comprehensible. For
these two factors, mRNA expression is in accordance with
protein expression.
IGF-R2 mRNA is only very weakly expressed in testicular
tissue and seminoma. CP of 55 to 65 show that this receptor
is rarely produced in this tissue. However, Zhou and Bondy
[11] could verify IGF-R2 mRNA by in situ hybridization in
normal testicular tissue. High CP can also be caused by
inhibition of the PCR reaction. But melting curve and gel
analysis showed no primer dimers, and sequencing resulted
in a clear specific product. However, we cannot exclude
tissue-specific inhibition of the reaction by unknown factors.
Studies in roe deer and goats suggest a specific role for
IGF in the paracrine control of spermatogenesis [24,25].
The pronounced expression of IGF-2 in terms of para-
nuclear vesicles in primary and secondary spermatocytes,
as well as in some Sertoli cells, implicates a similar role in
human testis. This concept is supported by the correlation
of IGF-2 and FSH-R expression, with the latter being a
Sertoli cell marker. Parts of the epididymis could be ana-
lyzed in two cases. The strong, luminal, and vesicular
Table 2. Expression Data (mRNA) for IGF-Related Genes Present on the Array in 43 Tissue Samples Regarding Different Tumor Stages.
Gene Probe Set ID NCBI ID Product P-call (%) NT pT1 pT2 pT3
Mean SD Mean SD Mean SD Mean SD
IGF-1 1501_at X57025 Complete cds 91 801 518 775 424 572 584 335 281
1975_s_at X03563 Potential IGF-1 precursor 88 906 371 1763 1303 1370 808 1755 1017
38737_at M14156 Exon 4 77 304 191 241 169 194 143 104 26
IGF-R1 1335_at X04434 Complete cds 2 271 91 125 129 99 73 412 424
34718_at X04434 Complete cds 100 510 127 518 282 484 299 864 678
IGF-2 1591_s_at J03242 Complete cds 0 96 19 76 71 60 63 92 89
2079_s_at M13970 Exon 1 of four 26 244 4 339 142 315 92 559 133
36782_s_at J03242 Complete cds 0 29 32 13 9 20 16 59 88
IGF-R2 160027_s_a Y00285 Complete cds 100 1295 98 1385 583 1250 397 893 380
IGFBP-1 1232_s_at M74587 Complete cds 42 90 24 93 42 80 38 95 20
IGFBP-2 1741_s_at S37730 Precursor 91 701 165 928 893 826 658 1570 1148
40422_at X16302 Complete cds 100 1450 248 1791 1436 1794 1279 2713 1536
IGFBP-3 1586_at M35878 Complete cds 79 426 96 934 663 581 365 513 520
37319_at M35878 Complete cds 79 501 246 1376 832 950 570 980 1050
IGFBP-4 1737_s_at M62403 Complete cds 88 1040 540 1424 736 915 432 1518 1370
39781_at U20982 Promoter and complete cds 100 3741 1876 4529 2072 2939 1163 3552 3412
IGFBP-5 1396_at L27560 3V UTR 81 2282 2229 839 685 576 510 945 1204
1601_s_at L27559 Partial exon 4 0 19 5 23 15 26 25 61 40
1677_at M65062 Complete cds 7 151 64 149 76 159 81 245 144
1678_g_at M65062 Complete cds 7 101 130 33 30 32 26 66 29
38650_at L27560 3V UTR 88 3003 3248 987 714 689 631 1237 1779
41420_at AF055033 Complete cds 9 112 149 45 34 47 28 70 63
IGFBP-6 1736_at M62402 Complete cds 65 566 459 525 634 379 274 315 248
Table 3. Pearson’s Correlation Coefficient for Expression of IGF-Related
Genes and Sertoli/Leydig Cell Markers in 43 Samples Measured by
Microarrays.
FSH-R AR AR DLK1 INSL3
IGF-1
IGF-R1 0.422**
IGF-2 0.354*
IGF-R2
IGFBP-1
IGFBP-2
IGFBP-3 0.328* 0.361*
0.318* 0.367*
IGFBP-4
IGFBP-5 0.510*** 0.357* 0.416** 0.516*** 0.703***
0.405** 0.437** 0.351* 0.453** 0.675***
0.415** 0.454** 0.514*** 0.672***
0.502*** 0.695***
IGFBP-6
Different correlation coefficients indicate results of multiple probe sets.
*P V .05.
**P V .01.
***P V .001.
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staining in the rete testis and the efferent ductuli suggests a
reabsorption of IGF-2 during the epididymal passage. Pos-
sibly IGF-2 is also involved in maintaining the function of the
epididymal epithelium.
IGF-2 mRNA was previously demonstrated by Northern
blot analysis in a small subset of germ cell tumors. In two of
three seminoma, IGF-2 was present. The most abundant
IGF-2 mRNA expression, however, was seen in one embry-
onal carcinoma case [13]. There are some references that
propose a crucial role for IGF-2 in tumor growth [5,6,8]. In
our study, mRNA expression results are somewhat contra-
dictory. In the microarray data, two probe sets covering the
complete coding sequence did not detect any IGF-2 expres-
sion, whereas one probe set covering exon 1 of four showed
a slight but significant increase in pT1 and pT3 stages. In
contrast, in real-time PCR, IGF-2 mRNA is 16-fold down-
regulated in seminoma compared to normal testicular tis-
sue. Immunohistochemistry is not a quantitative method, but
showed a weaker staining of tumor cells compared to
normal testis. Concerning IGF-2, the microarray seems to
be less sensitive than real-time PCR, and we regard the
real-time PCR and immunohistochemical results as more
reliable. Therefore, it seems to be unlikely that the tumor-
stimulating effects of IGF-2 play a major role in the growth
regulation of seminoma. These findings correspond to an
immunohistochemical study of Drescher et al. [14], who
found no IGF-2 staining in CIS—the precursor cells of
testicular germ cell tumors.
IGF-2 is bound by IGFBP-6 with a 100-fold higher affinity
than IGF-1 [10]. IGFBP-6 has primarily inhibiting effects on
tumor growth [26–28]. In seminoma, IGFBP-6 is constantly
expressed in microarray data and slightly downregulated
in RT-PCR data. This downregulation, however, is not as
pronounced as the IGF-2 decreases. Thus, the ratio of
IGFBP-6 to IGF-2 increases and therefore intensifies the
inhibition of tumor growth.
However, IGF-2 is the most strongly expressed mRNA,
when compared to the other IGF components, even in the
tumor tissue despite downregulation. RT-PCR cannot dis-
criminate which cells produce the measured target gene
expression. High expression levels may be caused by the
tumor cells themselves, or by any interstitial or vascular
tissue. The particular staining of endothelial cells of tumor
capillaries in seminoma supports the finding of Ritter et al.
[29] that IGF-2 is involved in tumor angiogenesis and streng-
thens the role of IGF-2 in tumor growth.
IGF-2 may act as an autocrine stimulator of tumor
growth through the activation of IR-A [5,8]. The constant
expression of IR-A and the pronounced downregulation of
IR-B increase the relative abundance for the IGF-2 binding
isoform A of the insulin receptor and therefore the mito-
genic potential.
IGFBP generally have, with some exceptions, a rather
inhibiting effect on IGF action in tumor tissues [1]. Thus, a
downregulation of IGFBP results in less inhibited IGF action,
increased binding of IGF to their receptors, and therefore
increased antiapoptosis, mitogenesis, and tumor growth. In
the case of a comparison between functional testicular tissue
and proliferating tumor tissue, a downregulation in the tumor
tissue may just reflect the lack of spermatogenesis. This
may, in particular, apply to IGFBP-5, whose expression
strongly correlates with Sertoli and Leydig cell markers.
IGFBP-5 can have IGF-inhibiting and IGF-stimulating effects
[30–32]. Its downregulation in seminoma may mean both a
stimulated tumor growth by less inhibition, or an inhibited
tumor growth by less stimulated mitogenesis. In an immuno-
histochemical study of CIS in the testis [14], IGFBP-5 was
identified as the most strongly expressed IGFBP. The
authors presume a prominent role of IGFBP-5 in the onset
of testicular germ cell tumor. Regarding the results of our
study, we can confirm the finding of IGFBP-5 to be the most
strongly expressed IGFBP. Considering the significant dif-
ference in mRNA expression between pT1 and pT2 stages,
IGFBP-5 may indeed also be involved in the progression of
tumor growth in seminoma—but rather because of its down-
regulation, not because of its strong expression. Further
studies (e.g., cell cultures) are needed to elucidate the
specific function of IGFBP-5 in seminoma.
Table 4. Comparison of Microarray and Real-Time PCR Data: mRNA Expression in Seminoma Compared to Normal Testis Regarding Data from the Literature.
Gene Microarray RT-PCR Literature
NT (n = 3), pT1 (n = 22),
pT2 (n = 14), pT3 (n = 4)
NT (n = 9), pT1 (n = 8),
pT2 (n = 14)
Testis [11] CIS [14]
IGF-1 Constant Constant mRNA not detected IHC positive
IGF-R1 Constant Constant mRNA in germinal epithelium
IGF-2 2 no expression, 1
increase in pT1 and pT3
Decreased mRNA in vessels, peritubular tissue,
and connective tissue
IHC negative
IGF-R2 Constant Constant mRNA in germinal epithelium
IGFBP-1 Constant Decreased Not detected IHC weak
IGFBP-2 Constant Constant In Leydig and Sertoli cells IHC positive
IGFBP-3 Increased in pT1,
slightly decreased in pT2 and pT3
Slightly increased in pT1,
decreased in pT2
mRNA in vessels IHC weakly positive
IGFBP-4 Slightly increased in pT1,
decreased in pT2
Decreased mRNA in vessels, Leydig cells, and connective tissue IHC weak
IGFBP-5 Decreased in pT1 and pT2 Decreased mRNA in connective tissue and little in Leydig cells IHC positive
IGFBP-6 Constant Decreased mRNA peritubular and interstitial IHC weak
IHC = immunohistochemistry.
IGF in Seminoma and Normal Testis Neuvians et al. 453
Neoplasia . Vol. 7, No. 5, 2005
In transgenic mice, overexpression of IGFBP-1 resulted
primarily in an inhibition of IGF action [33]. In prostate cancer
cell lines (LNCaP cells), IGFBP-1 reduces cell growth and
induces apoptosis by an IGF-dependent mechanism [34].
The mainly IGF-inhibiting role of IGFBP-1 implies that the
downregulation of IGFBP-1 in seminoma may be involved in
increased IGF action and tumor growth.
IGFBP-3 is the main intravascular carrier and storage for
IGF-1. Receptor binding of IGF is anticipated by forming
complexes with ALS. The successful treatment of breast
cancer with Tamoxifen, an antiestrogen, induces elevated
IGFBP-3 level and decreased IGFBP-3 proteolysis [35].
IGFBP-4 is a soluble, extracellular binding protein that
inhibits the IGF/IGF binding site interaction by sequestering
IGF. In malignant M12 epithelial cells of the prostate, over-
expression of IGFBP-4 caused delayed tumor cell growth
and increased apoptosis [36]. The correlation of both IGFBP
expressions suggests a common regulation. The down-
regulation of both IGFBP-3 and IGFBP-4 in seminoma may
contribute to a less inhibited tumor growth. The significant
downregulation of IGFBP-3 in pT2 stages compared to pT1
stages may indicate this participation in tumor progression.
The negative correlation of IGFBP-3 with the Sertoli cell
markers argues for an IGFBP-3 regulation that is indepen-
dent of functional spermatogenesis. The slight increase of
IGFBP-3 expression in pT1 stages compared to normal
testicular tissue may represent an attempt of counterregula-
tion to inhibit a stimulated tumor growth.
There are several evidences that IGF-R1 overexpression
is associated with tumor cell proliferation, adhesion, and
metastasis [1]. But as it is constantly expressed in normal
testicular tissue and seminoma, it does not seem to play a
major role for the growth of seminoma. However, germ cells
are a very active and proliferating tissue, and it is known
that the IGF system is involved in spermatogenesis [11,12].
Furthermore, IGF-R1 expression correlates with FSH-R
expression, a Sertoli cell marker, which is a hint that IGF-
R1 takes part in spermatogenesis. In the rather homoge-
nously growing classic seminoma, Sertoli cells no longer
exist. A missing downregulation in tumor tissue despite
lack of spermatogenesis could therefore indicate a major
role in tumor growth. Similar to IGF-R1, IGF-1 and IR-A do
not show any significant differences in mRNA expression
between normal tissue and seminoma.
There seem to be inhibiting and stimulating influences on
IGF function for IGFBP-2: in non small cell lung cancer cell
lines, IGFBP-2 inhibited the binding of IGF-1 and IGF-2 to
their receptor IGF-R1 [37], and may thereby inhibit tumor
growth. In contrast, glioblastoma cell lines overexpressing
IGFBP-2 showed an increase in invasion-related genes and
an increased invasion rate in cell culture experiments. It
therefore seems to contribute to glioma progression [38].
Figure 4. Representative immunohistochemically-stained tissue sections of
normal testicular tissue and seminoma. (A) Strong IGF-2 staining in terms of
paranuclear dots in primary and secondary spermatocytes and some Sertoli
cells; no staining of spermatogonia and seminoma. (B) Weak IGF-2 staining
of tumor cells and a distinct staining of endothelial cells of some smaller
capillaries; original magnification,  250.
Figure 5. Protein expression of IGFBP-5 in normal testicular tissue and pT1,
pT2, and pT1 + pT2 stages of seminoma. Data are shown as the integral of
optical density minus background (OD Int  Bkg). Significance is indicated as
follows: ***P < .001. Underneath, a representative blot with specific bands at
31 kDa for normal testicular tissue (NT1 and NT2) and seminoma (S1–S5).
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Similar to this finding, IGFBP-2 is overexpressed in prostate
carcinoma compared to normal prostate tissue [39], indicat-
ing an involvement in tumor growth. Due to its smaller
molecular size, IGFBP-2 can bring IGF-1 and IGF-2 into
extracellular avascular spaces where IGFBP-3 would be
sterically too big. There are also evidences that IGFBP-2
may be found in the nucleus and thereby influence IGF—
independently of apoptosis and cell survival [40]. There are
no differences in IGFBP-2 expression between normal tes-
ticular tissue and seminoma, although IGFBP-2 mRNA is
expressed in Leydig cells and Sertoli cells [11] that are not
retrievable in tumor tissue. The highly significant correlation
between IGF-R1 and IGFBP-2 expression suggests a major
role in seminoma for these factors.
In conclusion, we assume an important paracrine or
autocrine role of IGF-2 for human spermatogenesis. Genes
correlating with Sertoli and Leydig cell markers, such as
IGF-2 or IGFBP-5, seem to be involved in spermatogenesis
and may therefore be downregulated in seminoma. Con-
cerning the tumor growth of seminoma, the decrease of
mainly IGF-inhibiting IGFBP may contribute to stimulated
tumor growth. Constantly expressed genes, such as IGF-1,
IGF-R1, IR-A, and IGFBP-2, may reflect, on one hand, an
involvement in spermatogenesis and, on the other hand, a
major role in tumor growth as they do not decrease in
seminoma despite the missing spermatogenesis.
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